A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.
Originalsprog | Engelsk |
---|---|
Tidsskrift | New England Journal of Medicine |
Vol/bind | 362 |
Udgave nummer | 5 |
Sider (fra-til) | 416-26 |
Antal sider | 11 |
ISSN | 0028-4793 |
DOI | |
Status | Udgivet - 4 feb. 2010 |
ID: 34093028